Fidia Pharma USA Inc to exhibit at AAOS 2012 Annual Meeting
Fidia Pharma USA Inc will be exhibiting at the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) in San Francisco, February 7-11, 2012. Please come and see us at booth 4220 (Hall E).
We will be exhibiting our flagship product HYALGAN® (sodium hyaluronate, intra-articular injections for the treatment of pain in osteoarthritis of the
Fidia Pharma USA Inc to exhibit at 2011 ACR/ARHP Annual Scientific Meeting
Fidia Pharma USA Inc will be exhibiting at the forthcoming Annual Scientific Meeting of the American College of Rheumatology in Chicago, 5-9 November 2011. Please come and see us at booth 1032.
We will be exhibiting our flagship product HYALGAN® (sodium hyaluronate, intra-articular injections for the treatment of pain in osteoarthritis of the knee.
HYALGAN® is a
Hyalo GYN® Vaginal Hydrating gel available in the US
Fidia Pharma USA Inc, to distribute the product online
Hyalo GYN® supplements the body's natural hydrating function, and is intended for use as a hydrating /lubricating agent in patients suffering from vaginal dryness of various origins, and micro-lesions of the epithelium that can result from a poorly lubricated environment. It was developed especially for women whose
Fidia Farmaceutici S.p.A. to Distribute and Promote HYALGAN® (sodium hyaluronate) for Treatment of Osteoarthritis
Commercial rights to Hyalgan transitioned from Sanofi back to Fidia, the brand's owner and manufacturer
Wholly-owned subsidiary, Fidia Pharma USA Inc, engages Interpace BioPharma, LLC. to handle distribution and promotional support
PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire/ -- Fidia Farmaceutici S.p.A. ("Fidia") announced today that it has assumed responsibility for distributing and promoting the osteoarthritis (OA) treatment,